Sparsentan misses primary endpoint in FSGS
The pivotal phase 3 DUPLEX study with sparsentan in focal segmental glomerulosclerosis (FSGS) did not meet the primary endpoint over 108 weeks of treatment. Sparsentan was observed to have a 0.3 and a 0.9 mL/min/1.73m2 per year favourable difference on eGFR total slope and chronic slope respectivel
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.